NCT01435382View on ClinicalTrials.gov

A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

April 30, 2012

Conditions
HypercholesterolemiaDyslipidemiasHyperlipidemiasLipid Metabolism DisordersMetabolic Diseases
Interventions
BIOLOGICAL

PF-04950615 (RN316)

Dose A - single-dose intravenous infusion

BIOLOGICAL

PF-04950615 (RN316)

Dose B - single-dose subcutaneous injection

BIOLOGICAL

PF-04950615 (RN316)

Dose C - single-dose subcutaneous injection

BIOLOGICAL

PF-04950615 (RN316)

Dose D - single-dose subcutaneous injection

Trial Locations (7)

21225

PAREXEL International - Baltimore Early Phase Clinical Unit, Baltimore

33169

Elite Research Institute, Miami

45212

Medpace Clinical Pharmacology Unit, Cincinnati

49007

Jasper Clinic, Inc., Kalamazoo

55114

Prism Research, Saint Paul

66212

Vince and Associates Clinical Research, Overland Park

91911

Profil Institute for Clinical Research, Inc., Chula Vista

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01435382 - A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia | Biotech Hunter | Biotech Hunter